康艾注射液联合恩替卡韦治疗乙型病毒性肝炎相关性中晚期肝癌的临床疗效及安全性评价

发布时间：2018-05-14 16:14

本文选题：康艾注射液 + 恩替卡韦　；参考：《中国临床药理学杂志》2015年24期

【摘要】：目的评价康艾注射液联合恩替卡韦治疗对乙型病毒性肝炎(HBV)相关性中晚期肝癌的临床疗效及安全性。方法将72例HBV相关性中晚期肝癌患者随机分为试验组36例和对照组36例。对照组予以康艾注射液50 mL+5%葡萄糖注射液250 mL,静脉滴注,每天一次;试验组在对照组的基础上,加用口服恩替卡韦0.5 mg,每天一次。2组患者一个疗程均为4周,连续3个疗程。比较2组患者的临床疗效、治疗前后的肝功能、血常规和HBV-DNA水平,以及不良反应发生率。结果治疗后,试验组的临床总有效率50.00%明显高于对照组27.78%(P0.05)。治疗后,2组患者的肝功能、血常规和HBV-DNA水平均较治疗前显著改善(P0.05),且试验组上述指标优于对照组(P0.05)。2组患者不良反应类别和发生率比较差异无统计学意义(P0.05)。结论康艾注射液联合恩替卡韦治疗HBV相关性中晚期肝癌的临床疗效确切,且能有效地改善患者的肝功能、血常规和HBV-DNA水平。
[Abstract]:Objective to evaluate the clinical efficacy and safety of Kang ai injection combined with entecavir in the treatment of advanced liver cancer associated with hepatitis B (HBV). Methods 72 patients with HBV related advanced liver cancer were randomly divided into 36 cases in the experimental group and 36 cases in the control group. The control group was treated with 50 mL+5% Glucose Injection 250 mL, intravenous infusion, and the control group. On the basis of the control group, the experimental group was treated with oral entecavir 0.5 mg on the basis of the control group. One course of one course in group.2 each day was 4 weeks, and 3 courses of treatment. The clinical efficacy of the 2 groups, the liver function, the blood routine and the HBV-DNA level before and after treatment, and the adverse reaction rate were compared. The total clinical effective rate of the test group was 5 after the treatment. 0% significantly higher than the control group 27.78% (P0.05). After treatment, the liver function, blood routine and HBV-DNA level of the 2 groups were significantly improved (P0.05), and the above indexes in the experimental group were superior to the control group (P0.05) group.2. There was no significant difference between the group and the incidence of adverse reactions (P0.05). Conclusion Kang ai injection combined with entecavir. The treatment of HBV associated with advanced liver cancer is effective and effective in improving liver function, blood routine and HBV-DNA levels.

【作者单位】：莱芜市人民医院传染科;南昌市中心医院感染科;
【基金】：2012年度江西省医学会科研基金资助项目(2011-NO.B047)
【分类号】：R735.7;R512.62

【共引文献】